Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10709728-B2
Application number	US-201615578955-A
Country	US
Kind code	B2
Filing date	May 25, 2016
Priority date	Jun 1, 2015
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

The invention relates to polynucleotide agents, e.g., antisense polynucleotide agents, targeting an angiotensinogen (AGT) gene, and methods of using such polynucleotide agents to inhibit expression of AGT and to treat subjects having an AGT-associated disease, e.g., hypertension.

First claim

I claim:

1. A single-stranded antisense polynucleotide agent for inhibiting expression of angiotensinogen (AGT), wherein the single-stranded agent comprises 10 to 40 contiguous nucleotides, wherein at least one of the contiguous nucleotides is a modified nucleotide, wherein the nucleotide sequence of the agent is about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of nucleotides 1254-1273 of SEQ ID NO:1, and wherein the modified nucleotide comprises a modified internucleoside linkage.

2. The agent of claim 1 , wherein substantially all of the nucleotides of the antisense polynucleotide agent are modified nucleotides.

3. The agent of claim 1 , wherein all of the nucleotides of the antisense polynucleotide agent are modified nucleotides.

4. The agent of claim 1 , which is 10 to 30 nucleotides in length; 18 to 30 nucleotides in length; 10 to 24 nucleotides in length; 18 to 24 nucleotides in length; or 14 nucleotides in length.

5. The agent of claim 1 , wherein the modified nucleotide comprises a modified sugar moiety selected from the group consisting of: a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, and a bicyclic sugar moiety.

6. The agent of claim 5 , wherein the bicyclic sugar moiety has a (—CH2-)n group forming a bridge between the 2′ oxygen and the 4′ carbon atoms of the sugar ring, wherein n is 1 or 2.

7. The agent of claim 1 , wherein the modified nucleotide is a 5-methylcytosine.

8. The agent of claim 1 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

9. The agent of claim 1 , comprising a plurality of 2′-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.

10. The agent of claim 9 , wherein the agent is a gapmer comprising a gap segment comprised of linked 2′-deoxynucleotides positioned between a 5′ and a 3′ wing segment.

11. The agent of claim 9 , wherein the modified sugar moiety is selected from the group consisting of a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, and a bicyclic sugar moiety.

12. The agent of claim 10 , wherein the 5′-wing segment and the 3′-wing segment are each independently 1 to 6 nucleotides in length.

13. The agent of claim 10 , wherein the gap segment is 5 to 14 nucleotides in length.

14. The agent of claim 1 , wherein the agent further comprises a ligand.

15. The agent of claim 14 , wherein the antisense polynucleotide agent is conjugated to the ligand at the 3′-terminus.

16. The agent of claim 14 , wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.

17. The agent of claim 14 , wherein the ligand is

18. A pharmaceutical composition for inhibiting expression of an angiotensinogen (AGT) gene comprising the agent of any one of claims 1 , 2 - 4 , 5 - 7 , 8 - 12 , 13 , and 14 - 17 .

Assignees

• Alnylam Pharmaceuticals Inc

Inventors

• Hinkle Gregory

Classifications

• C12N15/1136

  against growth factors, growth regulators, cytokines, lymphokines or hormones · CPC title

• C12N2310/11

  Antisense · CPC title

• C12N2310/3341

  5-Methylcytosine · CPC title

• C12N2310/315

  Phosphorothioates · CPC title

• C12N2310/351

  Conjugate · CPC title